中文名称: | CDKI-73 | ||||
---|---|---|---|---|---|
英文名称: | CDKI-73 | ||||
别名: | LS-007 | ||||
CAS No: | 1421693-22-2 | 分子式: | C15H15FN6O2S2 | 分子量: | 394.45 |
CAS No: | 1421693-22-2 | ||||
分子式: | C15H15FN6O2S2 | ||||
分子量: | 394.45 |
基本信息
产品编号:C10824 |
|||||
产品名称:CDKI-73 |
|||||
CAS: |
1421693-22-2 |
储存条件 |
粉末 |
2-8℃ |
四年 |
分子式: |
溶于液体 |
-80℃ |
两年 |
||
分子量 |
394.45 |
-20℃ |
一个月 |
||
化学名: |
3-((5-fluoro-4-(4-methyl-2-(methylamino)thiazol-5-yl)pyrimidin-2-yl)amino)benzenesulfonamide |
||||
Solubility (25°C) |
体外 |
DMSO |
79mg/mL (200.27mM) |
||
Ethanol |
1.5mg/mL (3.8mM) |
||||
Water |
Insoluble |
||||
体内 |
现配现用 |
|
|||
<1mg/ml表示微溶或不溶。 |
|||||
普西唐提供的所有化合物浓度为内部测试所得,实际溶液度可能与公布值有所偏差,属于正常的批间细微差异现象。 |
|||||
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;⼀旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 |
制备储备液
浓度
溶液体积 质量 |
1mg |
5mg |
10mg |
1mM |
2.5352mL |
12.6759mL |
25.3518mL |
5mM |
0.5070mL |
2.5352mL |
5.0704mL |
10mM |
0.2535mL |
1.2676mL |
2.5352mL |
50mM |
0.0507mL |
0.2535mL |
0.5070mL |
生物活性
产品描述 |
具有口服活性的、高效的 CDK9 抑制剂,其对CDK9、CDK1 和 CDK2 的 Ki 值分别为 4nM、4nM 和 3nM。 |
||||
靶点/IC50 |
CDK2 |
CDK9 |
CDK1 |
CDK4 |
|
3.27nM |
5.78nM |
8.17nM |
8.18nM |
||
体外研究 |
CDKI-73 is highly cytotoxic to primary leukemia cells derived from CLL patients (mean LD50 = 0.08μM) and shows>500-fold selectivity for primary leukemia cells over normal B-lymphocytes (LD50 = 40.5μM). CDKI-73 (0.1μM, 4 h) inhibits the phosphorylation of serine 2 of RNA polymerase II and MCL1 protein expression in CLL cells. CDKI-73 induced caspase-dependent apoptosis that was preceded by dephosphorylation of cdk9 and serine 2 of RNA polymerase II. CDKI-73 is highly effective against all cell lines tested with an IC50 in the range of 0.012-0.517μM; in particular three MLLAML cell lines, namely MOLM13, MV4-11 and THP-1, were highly sensitive to CDKI-73 with IC50 values <0.062μM. Cell Viability Assay. |
||||
Cell Line: |
CLL cells. |
||||
Concentration: |
0-1μM. |
||||
Incubation Time: |
48 h. |
||||
Result: |
Shows preferential cytotoxicity in CLL cells. |
||||
体内研究 |
CDKI-73 (25, 50, 100 mg/kg) markedly decreases tumor growth in a dose-dependent manner and results in a prolongation of animal life span (P < 0.001) without causing body weight loss and other overt toxicities. |
||||
Animal Model: |
MV4-11 tumor bearing mice . |
||||
Dosage: |
25mg/kg. |
||||
Administration: |
Orally once everyday for 33 days. |
||||
Result: |
Caused a remarkable delay in tumor growth compared to vehicle-treated mice, as reflected in a percentage for the mean tumor volume in treated to control mice of 43% at day 31. |
||||
|
|||||
Animal Model: |
Balb/C mice aged 6-8 weeks. |
||||
Dosage: |
2mg/kg (IV), 10, 20 and 40mg/kg (PO). (Pharmacokinetic Analysis.) |
||||
Administration: |
IV and PO, single dose. |
||||
Result: |
The Cmax increased from 1.29 to 3.66μM at a mean time of 1 h and the area under the curve (AUC) of CDKI-73 increased from 3.51 to 12.8μM.h when the oral dose was escalated from 10 to 40mg/kg. CDKI-73 was eliminated from plasma with a mean terminal half-life (T1/2) of 2 h. Its oralbioavailability (F) ranged from 54 to 85% across the three doses. |
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)
摩尔浓度计算公式
用本工具协助配置特定浓度的溶液,使用的计算公式为:
开始浓度 x 开始体积 = 最终浓度 x 最终体积
稀释公式
稀释公式一般简略地表示为:C1V1 = C2V2 ( 输入 输出 )